Alpha-Mannosidosis Market Set for Steady Growth Through 2036 as LAMZEDE Uptake Expands and Newborn Screening Drives Earlier Diagnosis

DelveInsight's "Alpha-mannosidosis Market Insights, Epidemiology, and Market Forecast - 2036" report provides an in-depth understanding of alpha-mannosidosis, including historical and forecasted epidemiology, treatment practices, emerging therapies, market trends, and market opportunities across the 7MM: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Download DelveInsight's comprehensive Alpha-mannosidosis Market Report to explore the treatment landscape, key players, and future market outlook: https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Alpha-Mannosidosis Market Report
• The alpha-mannosidosis market is expected to witness moderate-to-steady growth during the forecast period 2026-2036, driven by increasing uptake of velmanase alfa-tycv (LAMZEDE), expansion of newborn screening programs, and sustained R&D activity in the lysosomal storage disorder space.
• As per secondary analysis, the prevalence of alpha-mannosidosis is estimated at approximately 1 in 500,000 people in the general population in the United States.
• Alpha-mannosidosis affects males and females equally and can potentially affect individuals of any ethnic group worldwide.
• In Italy, the estimated prevalence of alpha-mannosidosis ranges from approximately 1 in 250,000 to 1 in 1 million live births, highlighting its status as an ultra-rare lysosomal storage disorder.
• Velmanase alfa-tycv (LAMZEDE) by Chiesi Global Rare Diseases is the first and only approved enzyme replacement therapy for alpha-mannosidosis, providing recombinant human alpha-mannosidase to address non-CNS manifestations of the disease.
• In February 2023, Chiesi Farmaceutici S.p.A. reported that the US FDA approved velmanase alfa-tycv (LAMZEDE) for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.
• Despite LAMZEDE's commercial success, the development pipeline remains notably sparse, with only a limited number of preclinical programs under evaluation, leaving significant unmet needs for CNS-penetrating and potentially curative approaches.
• In 2025, the United States held a significant share of the overall 7MM alpha-mannosidosis market, a dominance projected to persist throughout the forecast period.
Access DelveInsight's in-depth Alpha-mannosidosis Market Analysis for a closer look at the treatment landscape: https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Alpha-Mannosidosis Market Report Overview
The Alpha-mannosidosis Market Report provides insights into current treatment practices, the approved therapy landscape, market share by therapy, and current and forecasted 7MM market size from 2022 to 2036.
The report also covers current treatment practices and algorithms, unmet needs, market opportunities, and factors influencing the future growth of the alpha-mannosidosis market.

Alpha-Mannosidosis Overview
Alpha-mannosidosis is a rare inherited lysosomal storage disorder caused by mutations in the MAN2B1 gene, leading to a deficiency of the enzyme alpha-D-mannosidase. This enzyme deficiency results in the accumulation of mannose-rich oligosaccharides in cells, causing progressive damage to multiple organs and tissues.
The disease follows an autosomal recessive inheritance pattern and exists along a clinical spectrum ranging from mild disease (Type 1) to severe disease (Type 3), with most patients presenting with the moderate form (Type 2).

Explore the current treatment landscape and clinical insights in the Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Alpha-Mannosidosis Market Report Provides Insights Into
• Detailed assessment of the current and prospective treatment landscape for alpha-mannosidosis.
• Market size and market share estimates by therapy.
• Evaluation of the approved therapy alongside limited preclinical pipeline activity.
• Detailed analysis of collaborations, regulatory approvals, patents, and registry data, including the SPARKLE registry.
• Assessment of key opportunities and unmet needs that may influence the future treatment landscape.

Alpha-Mannosidosis Companies
Key companies involved in the alpha-mannosidosis market include:
• Chiesi Farmaceutici S.p.A.
• Others

Alpha-Mannosidosis Market - Route of Administration
The Alpha-mannosidosis Market Report provides a therapeutic assessment of the approved therapy by route of administration.
• Intravenous infusion

Alpha-Mannosidosis Market - Molecule Type
Alpha-mannosidosis products have been categorized under the following molecule type:
• Recombinant proteins (alpha-mannosidase replacement)

Download DelveInsight's latest report to gain strategic insights into the treatment landscape and key developments: https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Alpha-Mannosidosis Market Report
• Coverage: 7MM - United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Alpha-mannosidosis Companies: Chiesi Farmaceutici S.p.A. and others
• Alpha-mannosidosis Therapies: Velmanase alfa-tycv (LAMZEDE) and others
• Alpha-mannosidosis Market Outlook: Moderate-to-steady growth during 2026-2036
• Therapeutic Assessment by Clinical Stage: Marketed therapy and limited preclinical pipeline

Find out more in DelveInsight's exclusive Alpha-mannosidosis Market Report: https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Introduction
2. Executive Summary
3. Alpha-mannosidosis: Overview
4. Epidemiology and Patient Burden Assessment
5. Alpha-mannosidosis Current Treatment Practices
6. Alpha-mannosidosis Marketed Drugs
7. Alpha-mannosidosis Pipeline Development Activities
8. Alpha-mannosidosis Market Outlook and Drug Uptake
9. Alpha-mannosidosis Market Access and Reimbursement
10. Latest KOL Views on Alpha-mannosidosis
11. Alpha-mannosidosis Qualitative Analysis
12. Alpha-mannosidosis Market Size and Forecast, 2022-2036
13. Alpha-mannosidosis Key Companies
14. Alpha-mannosidosis Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.